Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/48832
Title: Decision-maker perspectives on outcomes studied in leukaemia clinical trials : the response evaluation in leukaemia (REVALEU) study protocol
Authors: Said, Dylan
Borg, John Joseph
Attard Pizzuto, Maresca
Serracino-Inglott, Anthony
Keywords: Leukemia -- Treatment
Technology assessment, Biomedical -- Evaluation
Clinical trials -- Decision making
Issue Date: 2019-05
Publisher: University of Malta. Department of Pharmacy
Citation: Said, D., Borg, J. J., Attard Pizzuto, M., & Serracino-Inglott, A. (2019, May). Decision-maker perspectives on outcomes studied in leukaemia clinical trials: the response evaluation in leukaemia ((REVALEU) study protocol. Poster session presented at the Professional Society for Health Economics and Outcomes Research (ISPOR) 2019 conference, New Orleans, USA.
Abstract: A poster presentation about decision-maker perspectives on outcomes studied in leukaemia clinical trials: the response evaluation in leukaemia (REVALEU) study protocol. Objectives: Evidence of efficacy for antineoplastic agents may be valued differently by regulatory and health technology assessment (HTA) bodies in the European Union (EU), impacting decision-making and access to innovative therapies. The aim was to develop a study protocol to identify core efficacy outcomes prioritised by EU decision-makers for clinical trials (CTs) investigating leukaemic disorders.
URI: https://www.um.edu.mt/library/oar/handle/123456789/48832
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Decision_maker_perspectives_on_outcomes_studied_in_leukaemia_clinical_trials_2019.pdf1.72 MBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.